Adaptive Biotechnologies Corp
ADPTQ4 2024(ADPT Q3 FY2024)Derived10% AI
AI Revenue %
10%
AI Fair Value
$159.4M
AI Revenue (Q)
$12.4M
Total Revenue (Q)
$124.5M
Source: SEC EDGAR 10-Q Filing
View 10-Q on SEC.govAnalysis
Total revenue $46.4M. MRD: $37.5M. Immune Medicine: $9.0M. Applying 50% AI attribution to IM: $9.0M * 50% = $4.5M. AI Revenue % = $4.5M / $46.4M = 9.7%, rounded to 10%. The company reorganized into two segments in 2024, with explicit AI/ML usage described in IM segment for TCR-Antigen mapping.
Analyzed by claude-opus-4-6
Quoted Figures
MRD Revenue $37,470K, Immune Medicine Revenue $8,965K, Total $46,435K for Q3 2024
10-Q filed 2024-11-07, Segment Information note
AI Products Identified (Ring 1)
TCR-Antigen Map (AI/ML-driven immune receptor-disease mapping)Adaptive Immunosequencing (AI/ML analysis component)Precision immunology drug discovery (AI/ML-enabled)
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
clonoSEQ diagnostic test ($37.5M MRD segment)MRD Pharma testing services
Confidence Tier
DerivedCalculated from reported segments primarily serving AI